Gastric cancer: 10-year experience

Downloads

Published

2026-10-22

How to Cite

Moncayo, J. C., Vela, E. B., Coronel, J. J., Cobeñas, K., Game, R., & Ortiz, Ángel R. (2026). Gastric cancer: 10-year experience. Oncology Journal (Ecuador), 2(1), 33–38. Retrieved from https://roe-solca.ec/index.php/johs/article/view/901

Issue

Vol. 2 No. 1 (1994): June

Section

Original Articles

License

Copyright (c) 2026 Jorge C. Moncayo, Emilio B. Vela, Jorge J. Coronel, Kleber Cobeñas, Rosario Game, Ángel R. Ortiz

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors

  • Jorge C. Moncayo Hospital “Teodoro Maldonado Carbo”
  • Emilio B. Vela Hospital “Teodoro Maldonado Carbo”
  • Jorge J. Coronel Hospital “Teodoro Maldonado Carbo”
  • Kleber Cobeñas Hospital “Teodoro Maldonado Carbo”
  • Rosario Game Hospital “Teodoro Maldonado Carbo”
  • Ángel R. Ortiz Hospital “Teodoro Maldonado Carbo”

Keywords:

gastric cancer, combined therapy, chemotherapy alone

Abstract

One hundred and ten patients with gastric cancer were included in this study from January 1982 to December 1992, with a follow-up period of 5 to 126 months. There was a higher incidence in males, and the mean age was 59 years. The most important clinical feature was weight loss (78 %). At diagnosis, the mean duration of symptoms was 29.5 months.

The most commonly used and reliable diagnostic procedures were upper gastrointestinal series and gastroscopy with biopsy, with diagnostic rates of 93 % and 100 %, respectively. Most cases were adenocarcinomas (98 %), with a predominance of G2 and G3 tumors. The most common tumor locations were the lower third (36 %) and the middle third (30 %) of the stomach.

Carcinoma was diagnosed at stages III and IV in 86 % of patients. Ninety-seven patients underwent surgery (88 %), and 73 cases (75 %) received radical surgery. Complementary therapy was administered to 90 patients (82 %). Twenty-five patients in stage III, branch A, were treated with radiotherapy plus chemotherapy (RT + CT), while 20 patients in branch B received chemotherapy alone (CT).

The two-year survival rate for stage III was 61 % in branch A versus 35 % in branch B (p > 0.5). The five-year survival rates were 37 % and 35 %, respectively. Survival for stage IV was very poor.

Downloads

Download data is not yet available.

References

Waterhouse JAH. Epidemiology of gastric cancer. In: Preece PE, Cuschieri A, Wellwood JM, editors. Cancer of the Stomach. New York: Grune & Stratton; 1986.

Silverberg E. Cancer statistics, 1986. CA Cancer J Clin. 1986;36(1):9-25.

Moertel CG. Stomach. In: Holland JF, Frei E III, editors. Cancer Medicine. Philadelphia: Lea & Febiger; 1982. p. 1760-1774.

Devesa SS, Silverman DT. Cancer incidence and mortality trends in the United States, 1935-1974. J Natl Cancer Inst. 1978;60:545-561.

Dunham LJ, Bailar JC III. World maps of cancer mortality rates and frequency ratios. J Natl Cancer Inst. 1968;41(1):155-203.

Staszewski J. Migrant studies in alimentary tract cancer. Recent Results Cancer Res. 1971;39:85-97.

Haenszel W, Kurihara M, Segi M, et al. Stomach cancer among Japanese in Hawaii. J Natl Cancer Inst. 1972;49(4):969-988.

Haas JF, Schottenfeld D. Epidemiology of gastric cancer. In Gastrointestinal Tract Cancer. Sloan-Kettering Cancer Series. New York: Plenum Medical; 1978.

Slikoff IJ. Origin of Human Cancer. Book C. New York: Cold Spring Harbor Laboratory; 1977. p. 1765-1784.

Waterhouse JAH, Muir CS, Shanmugaratnam K, Powell J, editors. Cancer Incidence in Five Continents. Vol. IV. Lyon: International Agency for Research on Cancer; 1982.

Beahrs OH, Myers MH, editors. Manual for Staging of Cancer. Philadelphia: JB Lippincott; 1983. p. 67.

Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol. 1985.

LaDue JS, Murison PJ, McNeer G, et al. Symptomatology and diagnosis of gastric cancer. Arch Surg. 1950;60:305-335.

Shahon DB, Horowitz S, Kelly WD. Cancer of the stomach: an analysis of 1,152 cases. Surgery. 1956;39:204.

Clarke JS, Cruze K, El Farra S, Longmire WP Jr. The natural history and results of surgical therapy for carcinoma of the stomach: an analysis of 250 cases. Am J Surg. 1961;102(2):143-152.

Adashek K, Sanger J, Longmire WP Jr. Cancer of the stomach: review of consecutive ten-year intervals. Am J Surg. 1979.

Goldsmith HS, Ghosh BC. Carcinoma of the stomach. Am J Surg. 1970;120:317.

Kelsey JR. Cancer of the Stomach: A Clinical Guide for Diagnosis and Treatment. Springfield, IL: Charles C. Thomas; 1976.

Green PHC, et al. Early gastric cancer. Gastroenterology. 1981;81:24.

Cooley RN. The diagnostic accuracy of upper gastrointestinal radiology studies. Am J Med Sci. 1961;242:628.

Laufer I. Double contrast radiology in the diagnosis of gastrointestinal cancer. In: Glass J, editor. Progress in Gastroenterology. New York: Grune & Stratton; 1977. p. 643-669.

Laufer I. A simple method for routine double contrast study of the upper gastrointestinal tract. Radiology. 1975;117:513.

Winawer SJ, Melamed M, Sherlock P. Potential of endoscopy, biopsy and cytology in the diagnosis and management of patients with cancer. Clin Gastroenterol. 1976;5(3):575-595.

Winawer SJ, Sherlock P, Hayde SI. The role of upper gastrointestinal endoscopy in patients with cancer. Cancer. 1976;37:440.

McNeer G. The stomach. In: Nealon TF, editor. Management of the Patient with Cancer. Philadelphia: WB Saunders; 1965.

Piper DW, editor. Stomach cancer. In: UICC Reports Series. Geneva; 1978. p. 41.

Diehl JT, Hermann RE, Cooperman AM, et al. Gastric carcinoma: a ten-year review. Ann Surg. 1983;198:9-12.

Dupont JB, Cohn I Jr. Gastric adenocarcinoma. Curr Probl Cancer. 1980;4:25.

Longmire WP Jr. Total gastrectomy for carcinoma of the stomach. Surg Gynecol Obstet. 1947;84:21.

Miwa K. Advances in treatment of stomach carcinoma in Japan. In: Hirayama T, editor. Epidemiology of Stomach Cancer: Key Questions and Answers. Tokyo: WHO; 1977. p. 105-110.

Pack GT, McNeer G. Total gastrectomy for cancer: a collective review of the literature and original report of twenty cases. Int Abstr Surg. 1943;77:256.

Paulino F, Roelli A. Carcinoma of the stomach with special reference to total gastrectomy. Curr Probl Surg. 1973 Dec:1-72.

Rush BF Jr, Brown MW, Ravitch MM. Total gastrectomy: an evaluation of its use in the treatment of gastric cancer. Cancer. 1960;13:643.

Preusser P, Achterrath W, Wilke H, et al. Chemotherapy of gastric cancer. Treat Rev. 1988;15:257-277.

Gerard A. Clinical trials on gastrointestinal cancer in Western Europe and in the EORTC. Antibiot Chemother. 1978;24:160.

Moertel CG, Childs DS Jr, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor-prognosis gastric carcinoma. J Clin Oncol. 1984;2(11):1249-1254.

Gastrointestinal Tumor Study Group. A comparison of combination chemotherapy and combined-modality therapy for locally advanced gastric carcinoma. Cancer. 1982;49:1771-1777.

Falkson G. Halogenated pyrimidines as radiopotentiators in the treatment of stomach cancer. Prog Biochem Pharmacol. 1965;1:695-700.

Falkson G. Fluorouracil and radiotherapy in gastrointestinal cancer. Lancet. 1969:1252-1259.

Preusser P, Wilke H, Achterrath W, Neuhaus B, Balleisen L, Meyer J, Van de Loo J. Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin. Anticancer Res. 1986;6(5):1195-1196.

Preusser P, Wilke H, Achterrath W, Neuhaus B, Balleisen L, Meyer J, Van de Loo J. Advanced gastric carcinoma: a phase II study with etoposide (E), adriamycin (A) and split-course cisplatin (P) (EAP). Proc Am Soc Clin Oncol. 1987;6:75.